PCSK9 inhibition in high risk ASCVD – insights into patient selection

Sponsored by sanofi-aventis australia pty ltd

Ongoing analysis of data from the ODYSSEY OUTCOMES trial continues to shed light on the benefits of lowering elevated LDL-cholesterol (LDL-C) levels with the PCSK9 inhibitor alirocumab in patients at high risk of cardiovascular (CV) events.1-8 In this article, Professor Gerald Watts from the Royal Perth Hospital gives his impressions of the data. He also ...

Already a member?

Login to keep reading.

© 2021 the limbic